288 related articles for article (PubMed ID: 7970492)
1. CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse.
Vizcarra E; Lluch A; Cibrián R; Jarque F; García-Conde J
Oncology; 1994; 51(6):491-6. PubMed ID: 7970492
[TBL] [Abstract][Full Text] [Related]
2. Value of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis.
Vizcarra E; Lluch A; Cibrián R; Jarque F; Alberola V; Belloch V; García-Conde J
Breast Cancer Res Treat; 1996; 37(3):209-16. PubMed ID: 8825132
[TBL] [Abstract][Full Text] [Related]
3. Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients.
Pectasides D; Pavlidis N; Gogou L; Antoniou F; Nicolaides C; Tsikalakis D
Am J Clin Oncol; 1996 Oct; 19(5):459-64. PubMed ID: 8823487
[TBL] [Abstract][Full Text] [Related]
4. Assessment of CA 15.3, CEA and TPA concentrations during monitoring of breast cancer.
Sölétormos G; Petersen PH; Dombernowsky P
Clin Chem Lab Med; 2000 May; 38(5):453-63. PubMed ID: 10952230
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer.
Pedersen AC; Sørensen PD; Jacobsen EH; Madsen JS; Brandslund I
Clin Chem Lab Med; 2013 Jul; 51(7):1511-9. PubMed ID: 23403727
[TBL] [Abstract][Full Text] [Related]
6. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
7. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
[TBL] [Abstract][Full Text] [Related]
8. Comparison of tissue polypeptide antigen (TPA) with cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in follow-up of breast cancer.
Findeisen R; Albrecht S; Richter B; Deutschmann K; Distler W
Clin Chem Lab Med; 1998 Nov; 36(11):841-6. PubMed ID: 9877089
[TBL] [Abstract][Full Text] [Related]
9. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
10. CA 15-3 in human breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
Caponigro F; Iaffaioli RV; Pagliarulo C; De Placido S; Frasci G; Ungaro B; Matano E; Bianco AR
Int J Biol Markers; 1990; 5(2):73-6. PubMed ID: 2283480
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
12. Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer.
Kristiansen S; Jørgensen LM; Hansen MH; Nielsen D; Sölétormos G
Biomed Res Int; 2015; 2015():986024. PubMed ID: 26339655
[TBL] [Abstract][Full Text] [Related]
13. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA.
Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Winkel P; Mouridsen HT; Dombernowsky P
Ann Oncol; 1993 Dec; 4(10):861-9. PubMed ID: 8117606
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients.
Stieber P; Nagel D; Blankenburg I; Heinemann V; Untch M; Bauerfeind I; Di Gioia D
Clin Chim Acta; 2015 Aug; 448():228-31. PubMed ID: 26160053
[TBL] [Abstract][Full Text] [Related]
15. Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3.
Molina R; Jo J; Zanón G; Filella X; Farrus B; Muñoz M; Latre ML; Pahisa J; Velasco M; Fernandez P; Estapé J; Ballesta AM
Br J Cancer; 1996 Oct; 74(7):1126-31. PubMed ID: 8855986
[TBL] [Abstract][Full Text] [Related]
16. [CA 15-3 associated with CEA and TPA in the follow-up of breast carcinoma].
Maffei S; Rudoni M; Antonini G; Sacchetti G; Krengli M
Minerva Med; 1990 Nov; 81(11):759-63. PubMed ID: 2255409
[TBL] [Abstract][Full Text] [Related]
17. The role of CEA, TPA and CA 19-9 in the early detection of recurrent colorectal cancer.
Barillari P; Ramacciato G; de Angelis R; Gozzo P; Aurello P; Indinnimeo M; Valabrega S; D'Angelo F; Fegiz G
Int J Colorectal Dis; 1989 Dec; 4(4):230-3. PubMed ID: 2693562
[TBL] [Abstract][Full Text] [Related]
18. Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer.
Steger GG; Mader R; Derfler K; Moser K; Dittrich C
Klin Wochenschr; 1989 Aug; 67(16):813-7. PubMed ID: 2796251
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
20. Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations.
Nicolini A; Carpi A; Ferrari P; Pieri L
Tumour Biol; 2003; 24(6):275-80. PubMed ID: 15004486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
